Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment

Journal of Clinical Psychopharmacology

Volumn 17, Issue 3, 1997, Pages 149-155

  Egberts, Antoine C G ^a,b   Lenderink, Albert W ^c   De Koning, Fred H P ^a,b   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Netherlands Pharmacovigilance F   (Netherlands)

^c GGZ Midden Brabant   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FLUOXETINE; FLUVOXAMINE; HYPNOTIC AGENT; LITHIUM SALT; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; DEMOGRAPHY; DEPRESSION; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT CODING; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL;

1-NAPHTHYLAMINE; ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG UTILIZATION; HUMANS; MIANSERIN; MIDDLE AGED; NETHERLANDS; SERTRALINE;

EID: 0031004839     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199706000-00002     Document Type: Article

References (18)

1. Richelson E. Pharmacology of antidepressants. Characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
2. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994;46[suppl 1]:433-7.
3. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994;55[suppl A]:6-22.
4. Pies R. One foot on the bandwagon? J Clin Psychopharmacol 1995;15:303-5.
5. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
6. Petri H, Heerdink R, Leufkens HG, Kessels F, Urquhart J. Channeling of antidepressant drugs to patients with cardiovascular disease. Post Marketing Surveillance 1991;5:159-67.
7. Hernandez Avila M, Walker AM, Romieu I, Spiegelman DL, Perera DR, Jick H. Choice of non-steroidal anti-inflammatory drug in persons treated for dyspepsia Lancet 1988;332:556-9.
8. Leufkens HGM, Urquhart J, Stricker BH, Bakker A, Petri H. Channeling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastro-intestinal problems. J Epidemiol Community Health 1992;46:428-32.
9. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306:683-7.
10. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
11. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310:1433-8.
12. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-96.
13. Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Curr Ther 1994;16:715-30.
14. Stephens MDB. Detection of new adverse drug reactions. Hampshire, England: MacMillan Publishers Ltd, 1988.
15. Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785-7.
16. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994;46[suppl 1]:433-7.
17. Inman W, Pearce G. Prescriber profile and postmarketing surveillance. Lancet 1993;342:658-61.
18. Leufkens HGM, Urquhart J. Prescriber profile and postmarketing surveillance [letter]. Lancet 1993;342:1178.